perampanel 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antagonists of the ionotropic non-NMDA (N-methyl-D-aspartate) glutamate receptors (Namely the AMPA (amino-hydroxymethyl-isoxazole-propionic acid) and/or KA (kainite antagonist) receptors)	4684	380917-97-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: perampanel hydrate perampanel fycompa E2007 E-2007	a non-competitive AMPA glutamate receptor antagonist indicated as adjunctive therapy for the treatment of seizures Molecular weight: 349.39 Formula: C23H15N3O CLOGP: 3.87 LIPINSKI: 0 HAC: 4 HDO: 0 TPSA: 56.99 ALOGS: -4.80 ROTB: 3 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

perampanel hydrate
perampanel
fycompa
E2007
E-2007

a non-competitive AMPA glutamate receptor antagonist indicated as adjunctive therapy for the treatment of seizures

Molecular weight: 349.39
Formula: C23H15N3O
CLOGP: 3.87
LIPINSKI: 0
HAC: 4
HDO: 0
TPSA: 56.99
ALOGS: -4.80
ROTB: 3

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
8	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Hosey CM, Chan R, Benet LZ
Vd (Volume of distribution)	1.36 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.10 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.05 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	183 hours	Lombardo F, Berellini G, Obach RS
BA (Bioavailability)	1 %	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Approvals:

Date	Agency	Company
Jan. 23, 2020	PMDA	Eisai Co., Ltd.
Oct. 22, 2012	FDA	EISAI INC
July 23, 2012	EMA	EISAI GMBH

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Aggression	413.69	38.06	124	4380	23374	63461144
Multiple-drug resistance	314.38	38.06	73	4431	5097	63479421
Status epilepticus	292.29	38.06	86	4418	15147	63469371
Seizure	282.59	38.06	152	4352	132482	63352036
Irritability	205.09	38.06	79	4425	31615	63452903
Drug resistance	165.74	38.06	62	4442	22871	63461647
Suicidal ideation	128.14	38.06	70	4434	62351	63422167
Drug ineffective	124.15	38.06	244	4260	1044521	62439997
Epilepsy	95.92	38.06	44	4460	27021	63457497
Drug interaction	95.07	38.06	98	4406	229033	63255485
Suicide attempt	94.66	38.06	57	4447	60861	63423657
Psychotic disorder	91.74	38.06	42	4462	25670	63458848
Intentional overdose	86.78	38.06	58	4446	74094	63410424
Abnormal behaviour	85.99	38.06	38	4466	21388	63463130
Dizziness	79.98	38.06	123	4381	429802	63054716
Somnolence	78.72	38.06	79	4425	178606	63305912
Agitation	77.86	38.06	50	4454	59707	63424811
Anticonvulsant drug level increased	74.30	38.06	18	4486	1499	63483019
Mood altered	65.17	38.06	28	4476	14715	63469803
Ataxia	61.11	38.06	27	4477	15168	63469350
Generalised tonic-clonic seizure	60.73	38.06	33	4471	28983	63455535
Anger	56.19	38.06	24	4480	12432	63472086
Altered state of consciousness	53.64	38.06	29	4475	25201	63459317
Myoclonic epilepsy	42.09	38.06	11	4493	1243	63483275
Off label use	41.62	38.06	123	4381	674339	62810179
Drug withdrawal convulsions	40.70	38.06	11	4493	1414	63483104
Lipids abnormal	39.65	38.06	8	4496	285	63484233
Partial seizures	39.27	38.06	15	4489	5827	63478691

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Aggression	561.00	39.64	202	4143	38762	34913824
Status epilepticus	272.92	39.64	89	4256	12525	34940061
Seizure	239.15	39.64	153	4192	104704	34847882
Multiple-drug resistance	212.46	39.64	60	4285	5179	34947407
Suicide attempt	166.70	39.64	86	4259	39030	34913556
Irritability	133.90	39.64	64	4281	24626	34927960
Epilepsy	132.88	39.64	61	4284	21434	34931152
Anger	127.85	39.64	50	4295	11834	34940752
Drug ineffective	120.23	39.64	207	4138	456544	34496042
Somnolence	104.73	39.64	96	4249	111020	34841566
Anticonvulsant drug level above therapeutic	89.40	39.64	20	4325	662	34951924
Excessive eye blinking	87.72	39.64	19	4326	540	34952046
Intentional overdose	87.53	39.64	59	4286	43615	34908971
Partial seizures	84.56	39.64	29	4316	4731	34947855
Homicidal ideation	79.04	39.64	24	4321	2658	34949928
Suicidal ideation	74.84	39.64	52	4293	40336	34912250
Gaze palsy	66.60	39.64	19	4326	1693	34950893
Pneumonia aspiration	66.27	39.64	49	4296	41854	34910732
Psychotic disorder	63.71	39.64	39	4306	24413	34928173
Posture abnormal	61.57	39.64	19	4326	2220	34950366
Agitation	60.66	39.64	53	4292	57346	34895240
Generalised tonic-clonic seizure	53.19	39.64	33	4312	21141	34931445
Abnormal behaviour	53.02	39.64	35	4310	24934	34927652
Focal dyscognitive seizures	52.25	39.64	15	4330	1366	34951220
Ataxia	49.11	39.64	27	4318	13826	34938760
Behaviour disorder	46.98	39.64	19	4326	4891	34947695
Sudden unexplained death in epilepsy	41.33	39.64	10	4335	468	34952118
Drug withdrawal convulsions	41.05	39.64	12	4333	1165	34951421

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Aggression	849.84	30.24	280	7747	50678	79685683
Status epilepticus	458.61	30.24	148	7879	24893	79711468
Seizure	437.50	30.24	258	7769	188576	79547785
Multiple-drug resistance	431.61	30.24	112	7915	8696	79727665
Irritability	255.58	30.24	110	7917	41034	79695327
Suicide attempt	230.69	30.24	128	7899	82804	79653557
Drug ineffective	212.61	30.24	383	7644	1080530	78655831
Epilepsy	204.76	30.24	94	7933	40766	79695595
Suicidal ideation	175.21	30.24	104	7923	76236	79660125
Intentional overdose	162.67	30.24	112	7915	105848	79630513
Somnolence	155.16	30.24	153	7874	238828	79497533
Anger	151.25	30.24	59	7968	17103	79719258
Agitation	126.76	30.24	94	7933	99621	79636740
Drug resistance	119.52	30.24	66	7961	42147	79694214
Drug interaction	115.64	30.24	173	7854	415010	79321351
Abnormal behaviour	111.58	30.24	60	7967	36361	79700000
Partial seizures	108.82	30.24	39	7988	8939	79727422
Psychotic disorder	104.38	30.24	60	7967	41342	79695019
Generalised tonic-clonic seizure	98.50	30.24	59	7968	43851	79692510
Ataxia	96.10	30.24	48	7979	24991	79711370
Anticonvulsant drug level increased	88.79	30.24	25	8002	2628	79733733
Anticonvulsant drug level above therapeutic	82.82	30.24	20	8007	1151	79735210
Excessive eye blinking	80.19	30.24	21	8006	1680	79734681
Petit mal epilepsy	77.48	30.24	27	8000	5700	79730661
Dizziness	72.77	30.24	162	7865	526279	79210082
Altered state of consciousness	71.11	30.24	48	7979	43774	79692587
Focal dyscognitive seizures	69.26	30.24	22	8005	3490	79732871
Pneumonia aspiration	67.34	30.24	55	7972	66912	79669449
Gaze palsy	64.16	30.24	20	8007	2985	79733376
Sudden unexplained death in epilepsy	60.82	30.24	14	8013	654	79735707
Drug withdrawal convulsions	56.88	30.24	17	8010	2203	79734158
Seizure cluster	56.36	30.24	12	8015	390	79735971
Hostility	56.21	30.24	17	8010	2293	79734068
Posture abnormal	55.29	30.24	19	8008	3847	79732514
Hyperammonaemia	53.87	30.24	25	8002	11068	79725293
Homicidal ideation	53.40	30.24	18	8009	3439	79732922
Product administered to patient of inappropriate age	52.13	30.24	20	8007	5533	79730828
Mood altered	50.74	30.24	28	7999	17819	79718542
Pain	50.30	30.24	6	8021	703796	79032565
Off label use	48.86	30.24	200	7827	907015	78829346
Behaviour disorder	46.22	30.24	19	8008	6294	79730067
Dyspnoea	45.35	30.24	15	8012	857010	78879351
Hyperammonaemic encephalopathy	44.09	30.24	17	8010	4765	79731596
Hallucination, auditory	36.78	30.24	24	8003	20669	79715692
Drug level decreased	36.61	30.24	21	8006	14381	79721980
Physical assault	35.56	30.24	11	8016	1600	79734761
Partial seizures with secondary generalisation	35.51	30.24	9	8018	632	79735729
Malaise	35.39	30.24	4	8023	489865	79246496
Cognitive disorder	34.88	30.24	39	7988	69887	79666474
Haematuria traumatic	34.09	30.24	7	8020	190	79736171
Arthralgia	33.92	30.24	8	8019	571795	79164566
Diarrhoea	33.54	30.24	24	8003	880465	78855896
Craniocerebral injury	32.56	30.24	14	8013	5182	79731179
Lipids abnormal	30.88	30.24	8	8019	613	79735748

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N03AX22	NERVOUS SYSTEM ANTIEPILEPTICS ANTIEPILEPTICS Other antiepileptics
FDA MoA	N0000020016	AMPA Receptor Antagonists
FDA MoA	N0000182141	Cytochrome P450 3A4 Inhibitors
FDA EPC	N0000186106	Noncompetitive AMPA Glutamate Receptor Antagonist
FDA MoA	N0000187062	Cytochrome P450 2C8 Inhibitors
FDA MoA	N0000191273	UGT2B7 Inhibitors
FDA MoA	N0000191278	UGT1A9 Inhibitors
CHEBI has role	CHEBI:35623	anticonvulsants
CHEBI has role	CHEBI:71014	alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonists

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID
Secondarily generalized seizures	indication	20544001
Partial seizure	indication	29753000
Idiopathic generalized epilepsy	indication	36803009

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.89	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
10MG	FYCOMPA	CATALYST PHARMS	N202834	Oct. 22, 2012	RX	TABLET	ORAL	6949571	June 8, 2024	TREATMENT OF EPILEPSY
10MG	FYCOMPA	CATALYST PHARMS	N202834	Oct. 22, 2012	RX	TABLET	ORAL	6949571	June 8, 2024	TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY
10MG	FYCOMPA	CATALYST PHARMS	N202834	Oct. 22, 2012	RX	TABLET	ORAL	6949571	June 8, 2024	TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY 4 YEARS OF AGE AND OLDER
10MG	FYCOMPA	CATALYST PHARMS	N202834	Oct. 22, 2012	RX	TABLET	ORAL	6949571	June 8, 2024	TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY
10MG	FYCOMPA	CATALYST PHARMS	N202834	Oct. 22, 2012	RX	TABLET	ORAL	6949571	June 8, 2024	TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER
12MG	FYCOMPA	CATALYST PHARMS	N202834	Oct. 22, 2012	RX	TABLET	ORAL	6949571	June 8, 2024	TREATMENT OF EPILEPSY
12MG	FYCOMPA	CATALYST PHARMS	N202834	Oct. 22, 2012	RX	TABLET	ORAL	6949571	June 8, 2024	TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY
12MG	FYCOMPA	CATALYST PHARMS	N202834	Oct. 22, 2012	RX	TABLET	ORAL	6949571	June 8, 2024	TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY 4 YEARS OF AGE AND OLDER
12MG	FYCOMPA	CATALYST PHARMS	N202834	Oct. 22, 2012	RX	TABLET	ORAL	6949571	June 8, 2024	TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY
12MG	FYCOMPA	CATALYST PHARMS	N202834	Oct. 22, 2012	RX	TABLET	ORAL	6949571	June 8, 2024	TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER
2MG	FYCOMPA	CATALYST PHARMS	N202834	Oct. 22, 2012	RX	TABLET	ORAL	6949571	June 8, 2024	TREATMENT OF EPILEPSY
2MG	FYCOMPA	CATALYST PHARMS	N202834	Oct. 22, 2012	RX	TABLET	ORAL	6949571	June 8, 2024	TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY
2MG	FYCOMPA	CATALYST PHARMS	N202834	Oct. 22, 2012	RX	TABLET	ORAL	6949571	June 8, 2024	TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY 4 YEARS OF AGE AND OLDER
2MG	FYCOMPA	CATALYST PHARMS	N202834	Oct. 22, 2012	RX	TABLET	ORAL	6949571	June 8, 2024	TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY
2MG	FYCOMPA	CATALYST PHARMS	N202834	Oct. 22, 2012	RX	TABLET	ORAL	6949571	June 8, 2024	TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER
4MG	FYCOMPA	CATALYST PHARMS	N202834	Oct. 22, 2012	RX	TABLET	ORAL	6949571	June 8, 2024	TREATMENT OF EPILEPSY
4MG	FYCOMPA	CATALYST PHARMS	N202834	Oct. 22, 2012	RX	TABLET	ORAL	6949571	June 8, 2024	TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY
4MG	FYCOMPA	CATALYST PHARMS	N202834	Oct. 22, 2012	RX	TABLET	ORAL	6949571	June 8, 2024	TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY 4 YEARS OF AGE AND OLDER
4MG	FYCOMPA	CATALYST PHARMS	N202834	Oct. 22, 2012	RX	TABLET	ORAL	6949571	June 8, 2024	TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY
4MG	FYCOMPA	CATALYST PHARMS	N202834	Oct. 22, 2012	RX	TABLET	ORAL	6949571	June 8, 2024	TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER
6MG	FYCOMPA	CATALYST PHARMS	N202834	Oct. 22, 2012	RX	TABLET	ORAL	6949571	June 8, 2024	TREATMENT OF EPILEPSY
6MG	FYCOMPA	CATALYST PHARMS	N202834	Oct. 22, 2012	RX	TABLET	ORAL	6949571	June 8, 2024	TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY
6MG	FYCOMPA	CATALYST PHARMS	N202834	Oct. 22, 2012	RX	TABLET	ORAL	6949571	June 8, 2024	TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY 4 YEARS OF AGE AND OLDER
6MG	FYCOMPA	CATALYST PHARMS	N202834	Oct. 22, 2012	RX	TABLET	ORAL	6949571	June 8, 2024	TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY
6MG	FYCOMPA	CATALYST PHARMS	N202834	Oct. 22, 2012	RX	TABLET	ORAL	6949571	June 8, 2024	TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER
8MG	FYCOMPA	CATALYST PHARMS	N202834	Oct. 22, 2012	RX	TABLET	ORAL	6949571	June 8, 2024	TREATMENT OF EPILEPSY
8MG	FYCOMPA	CATALYST PHARMS	N202834	Oct. 22, 2012	RX	TABLET	ORAL	6949571	June 8, 2024	TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY
8MG	FYCOMPA	CATALYST PHARMS	N202834	Oct. 22, 2012	RX	TABLET	ORAL	6949571	June 8, 2024	TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY 4 YEARS OF AGE AND OLDER
8MG	FYCOMPA	CATALYST PHARMS	N202834	Oct. 22, 2012	RX	TABLET	ORAL	6949571	June 8, 2024	TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY
8MG	FYCOMPA	CATALYST PHARMS	N202834	Oct. 22, 2012	RX	TABLET	ORAL	6949571	June 8, 2024	TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER
0.5MG/ML	FYCOMPA	CATALYST PHARMS	N208277	April 29, 2016	RX	SUSPENSION	ORAL	6949571	June 8, 2024	TREATMENT OF EPILEPSY
0.5MG/ML	FYCOMPA	CATALYST PHARMS	N208277	April 29, 2016	RX	SUSPENSION	ORAL	6949571	June 8, 2024	TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY
0.5MG/ML	FYCOMPA	CATALYST PHARMS	N208277	April 29, 2016	RX	SUSPENSION	ORAL	6949571	June 8, 2024	TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY 4 YEARS OF AGE AND OLDER
0.5MG/ML	FYCOMPA	CATALYST PHARMS	N208277	April 29, 2016	RX	SUSPENSION	ORAL	6949571	June 8, 2024	TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY
0.5MG/ML	FYCOMPA	CATALYST PHARMS	N208277	April 29, 2016	RX	SUSPENSION	ORAL	6949571	June 8, 2024	TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Glutamate receptor ionotropic AMPA	Ion channel	P42261 P42262 P42263 P48058	GRIA1_HUMAN GRIA2_HUMAN GRIA3_HUMAN GRIA4_HUMAN	ANTAGONIST	IC50	6.61		CHEMBL	CHEMBL

External reference:

ID	Source
D08964	KEGG_DRUG
4032964	VUID
N0000189940	NUI
4032964	VANDF
CHEBI:71013	CHEBI
6ZP	PDB_CHEM_ID
CHEMBL1214124	ChEMBL_ID
C551441	MESH_SUPPLEMENTAL_RECORD_UI
7050	IUPHAR_LIGAND_ID
8834	INN_ID
DB08883	DRUGBANK_ID
H821664NPK	UNII
1356552	RXNORM
192918	MMSL
28817	MMSL
d07904	MMSL
014644	NDDF
703127006	SNOMEDCT_US
703728005	SNOMEDCT_US
C2698764	UMLSCUI
9924495	PUBCHEM_CID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Fycompa	HUMAN PRESCRIPTION DRUG LABEL	1	62856-272	TABLET	2 mg	ORAL	NDA	37 sections
Fycompa	HUMAN PRESCRIPTION DRUG LABEL	1	62856-272	TABLET	2 mg	ORAL	NDA	37 sections
Fycompa	HUMAN PRESCRIPTION DRUG LABEL	1	62856-274	TABLET	4 mg	ORAL	NDA	37 sections
Fycompa	HUMAN PRESCRIPTION DRUG LABEL	1	62856-274	TABLET	4 mg	ORAL	NDA	37 sections
Fycompa	HUMAN PRESCRIPTION DRUG LABEL	1	62856-276	TABLET	6 mg	ORAL	NDA	37 sections
Fycompa	HUMAN PRESCRIPTION DRUG LABEL	1	62856-276	TABLET	6 mg	ORAL	NDA	37 sections
Fycompa	HUMAN PRESCRIPTION DRUG LABEL	1	62856-278	TABLET	8 mg	ORAL	NDA	37 sections
Fycompa	HUMAN PRESCRIPTION DRUG LABEL	1	62856-278	TABLET	8 mg	ORAL	NDA	37 sections
Fycompa	HUMAN PRESCRIPTION DRUG LABEL	1	62856-280	TABLET	10 mg	ORAL	NDA	37 sections
Fycompa	HUMAN PRESCRIPTION DRUG LABEL	1	62856-280	TABLET	10 mg	ORAL	NDA	37 sections
Fycompa	HUMAN PRESCRIPTION DRUG LABEL	1	62856-282	TABLET	12 mg	ORAL	NDA	37 sections
Fycompa	HUMAN PRESCRIPTION DRUG LABEL	1	62856-282	TABLET	12 mg	ORAL	NDA	37 sections
Fycompa	HUMAN PRESCRIPTION DRUG LABEL	1	62856-290	SUSPENSION	0.50 mg	ORAL	NDA	37 sections
Fycompa	HUMAN PRESCRIPTION DRUG LABEL	1	62856-290	SUSPENSION	0.50 mg	ORAL	NDA	37 sections
Fycompa	HUMAN PRESCRIPTION DRUG LABEL	1	69616-272	TABLET	2 mg	ORAL	NDA	21 sections
Fycompa	HUMAN PRESCRIPTION DRUG LABEL	1	69616-274	TABLET	4 mg	ORAL	NDA	21 sections
Fycompa	HUMAN PRESCRIPTION DRUG LABEL	1	69616-276	TABLET	6 mg	ORAL	NDA	21 sections
Fycompa	HUMAN PRESCRIPTION DRUG LABEL	1	69616-278	TABLET	8 mg	ORAL	NDA	21 sections
Fycompa	HUMAN PRESCRIPTION DRUG LABEL	1	69616-280	TABLET	10 mg	ORAL	NDA	21 sections
Fycompa	HUMAN PRESCRIPTION DRUG LABEL	1	69616-282	TABLET	12 mg	ORAL	NDA	21 sections
Fycompa	HUMAN PRESCRIPTION DRUG LABEL	1	69616-290	SUSPENSION	0.50 mg	ORAL	NDA	21 sections